(Q33815739)

29 July 2017

1 reference

title

Review article: nitroimidazole resistance in Helicobacter pylori (English)

1 reference

Helicobacter pylori infectious disease

29 July 2017

0 references

1 reference

Van Der Wouden EJ

1

1 reference

29 July 2017

Thijs JC

series ordinal

2

1 reference

29 July 2017

Van Zwet AA

series ordinal

3

1 reference

29 July 2017

Kleibeuker JH

series ordinal

4

1 reference

29 July 2017

language of work or name

English

0 references

publication date

1 January 2000

1 reference

Alimentary Pharmacology & Therapeutics

29 July 2017

1 reference

29 July 2017

14

1 reference

29 July 2017

1

1 reference

29 July 2017

7-14

1 reference

Unidentified curved bacilli on gastric epithelium in active chronic gastritis

29 July 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00675.X

Review article: symptom improvement through eradication of Helicobacter pylori in patients with non-ulcer dyspepsia

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00675.X

Lack of effect of treating Helicobacter pylori infection in patients with nonulcer dyspepsia. Omeprazole plus Clarithromycin and Amoxicillin Effect One Year after Treatment (OCAY) Study Group.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00675.X

AGA technical review: evaluation of dyspepsia. American Gastroenterological Association

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00675.X

Modelling cost-effectiveness of Helicobacter pylori screening to prevent gastric cancer: a mandate for clinical trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00675.X

Treatment of Helicobacter pylori infection: a review of the world literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00675.X

Will Helicobacter pylori be the next organism for which we will have exhausted our treatment options?

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00675.X

Symposium on antimicrobial agents. Metronidazole

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00675.X

Metabolic activities of metronidazole-sensitive and -resistant strains of Helicobacter pylori: repression of pyruvate oxidoreductase and expression of isocitrate lyase activity correlate with resistance

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00675.X

How Helicobacter pylori works: an overview of the metabolism of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00675.X

The complete genome sequence of the gastric pathogen Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00675.X

Metronidazole resistance in Helicobacter pylori is due to null mutations in a gene (rdxA) that encodes an oxygen-insensitive NADPH nitroreductase.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00675.X

Metronidazole uptake by sensitive and resistant isolates of Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00675.X

Nitroimidazole drugs-action and resistance mechanisms I. Mechanism of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00675.X

Life (and death) in the Fas lane

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00675.X

Isolation of a genetic locus associated with metronidazole resistance in Helicobacter pylori.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00675.X

Antibiotic resistance in Helicobacter pylori: implications for therapy.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00675.X

Metronidazole susceptibility in Helicobacter pylori.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00675.X

The E test for antimicrobial susceptibility testing of Helicobacter pylori.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00675.X

Explanations for high rates of eradication with triple therapy using metronidazole in patients harboring metronidazole-resistant Helicobacter pylori strains

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00675.X

Resistance of Helicobacter pylori to antibiotics

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00675.X

In vitro activity of metronidazole against Helicobacter pylori as determined by agar dilution and agar diffusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00675.X

Comparison of three methods for the determination of the sensitivity of Helicobacter pylori to metronidazole.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00675.X

Validation of a modified Kirby-Bauer disk diffusion method for metronidazole susceptibility testing of Helicobacter pylori.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00675.X

Antimicrobial resistance testing of Helicobacter pylori: a comparison of Etest and disk diffusion methods.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00675.X

Prevalence of metronidazole-resistant Helicobacter pylori in dyspeptic patients.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00675.X

Standardization of disk diffusion test and its clinical significance for susceptibility testing of metronidazole against Helicobacter pylori

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00675.X

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00675.X

Metronidazole- and clarithromycin-resistant Helicobacter pylori in dyspeptic patients in western Sydney as determined by testing multiple isolates from different gastric sites

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00675.X

The influence of metronidazole resistance on the efficacy of ranitidine bismuth citrate triple therapy regimens for Helicobacter pylori infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00675.X

High prevalence of Helicobacter pylori metronidazole resistance in migrants to east London: relation with previous nitroimidazole exposure and gastroduodenal disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00675.X

Role of metronidazole resistance in therapy of Helicobacter pylori infections

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00675.X

Rapid increase in the prevalence of metronidazole-resistant Helicobacter pylori in the Netherlands

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00675.X

Prevalence of metronidazole resistant Helicobacter pylori strains among Chinese peptic ulcer disease patients and normal controls in Hong Kong

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00675.X

The influence of in vitro nitroimidazole resistance on the efficacy of nitroimidazole-containing anti-Helicobacter pylori regimens: a meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00675.X

Susceptibility of Helicobacter pylori isolates to metronidazole, clarithromycin and amoxycillin in vitro and in clinical treatment in Japan.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00675.X

Prevention of nitroimidazole resistance in Campylobacter pylori by coadministration of colloidal bismuth subcitrate: clinical and in vitro studies

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00675.X

Antiretroviral drugs for AIDS.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00675.X

Furazolidone-containing short-term triple therapies are effective in the treatment of Helicobacter pylori infection.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00675.X

High cure rate of Helicobacter pylori infection using tripotassium dicitrato bismuthate, furazolidone and clarithromycin triple therapy for 1 week.

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00675.X

Low cure rate of Helicobacter pylori infection with omeprazole and furazolidone dual therapy for one week

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00675.X

Sudden death due to metronidazole/ethanol interaction

21 January 2018

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2000.00675.X

10.1046/J.1365-2036.2000.00675.X

21 January 2018

Identifiers

DOI

1 reference

29 July 2017

1 reference